EyeGate Pharma Enrolls First Patient In Confirmatory Phase 3 Clinical Trial EGP-437-006 For Non-Infectious Anterior Uveitis
Data Anticipated Q1 2017 WALTHAM, Mass., Jan. 19, 2016 — Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that the first patient was enrolled in the Company’s confirmatory Phase 3 clinical trial…